Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Detection of genomic rearrangements from targeted resequencing data in Parkinson's disease patients

  • Spataro, Nino|||0000-0002-2127-2238
  • Roca-Umbert, Ana
  • Cervera Carles, Laura|||0000-0003-2286-200X
  • Vallès, Mònica
  • Anglada, Roger
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Pascual Sedano, Berta María|||0000-0002-9298-8241
  • Campolongo, Antonia|||0000-0002-7962-3264
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Casals, Ferran|||0000-0002-8941-0369
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Bosch, Elena|||0000-0003-2848-103X
The analysis of coverage depth in next-generation sequencing data allows the detection of gene dose alterations. We explore the frequency of such structural events in a Spanish cohort of sporadic PD cases. Gene dose alterations were detected with the eXome-Hidden Markov Model (XHMM) software from depth of coverage in resequencing data available for 38 Mendelian and other risk PD loci in 394 individuals (249 cases and 145 controls) and subsequently validated by quantitative PCR. We identified 10 PD patients with exon dosage alterations in PARK2, GBA-GBAP1, and DJ1. Additional functional variants, including 2 novel nonsense mutations (p.Arg1552Ter in LRRK2 and p.Trp90Ter in PINK1), were confirmed by Sanger sequencing. This combined approach disclosed the genetic cause of 12 PD cases. Gene dose alterations related to PD can be correctly identified from targeting resequencing data. This approach substantially improves the detection rate of cases with causal genetic alterations. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Deleterious ABCA7 mutations and transcript rescue mechanisms in early onset Alzheimer's disease

  • De Roeck, Arne
  • Van den Bossche, Tobi
  • Van der Zee, Julie|||0000-0003-4381-8040
  • Verheijen, Jan
  • De Coster, Wouter
  • Van Dongen, Jasper|||0000-0001-5599-0046
  • Dillen, Lubina
  • Baradaran-Heravi, Yalda
  • Heeman, Bavo
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Nacmias, Benedetta|||0000-0001-9338-9040
  • Sorbi, Sandro|||0000-0002-0380-6670
  • Gelpi, Ellen|||0000-0003-2948-4187
  • Grau-Rivera, Oriol|||0000-0002-4730-5341
  • Gómez-Tortosa, Estrella
  • Pastor, Pau|||0000-0002-7493-8777
  • Ortega-Cubero, Sara|||0000-0003-0520-9439
  • Pastor, Maria A.|||0000-0003-2404-9346
  • Graff, Caroline|||0000-0002-9949-2951
  • Thonberg, Håkan|||0000-0003-4503-4717
  • Benussi, Luisa|||0000-0003-2836-8141
  • Ghidoni, Roberta|||0000-0002-7691-1957
  • Binetti, Giuliano|||0000-0003-2759-5844
  • de Mendonça, Alexandre|||0000-0002-0488-1453
  • Martins, Madalena|||0000-0001-8360-6806
  • Borroni, Barbara|||0000-0001-9340-9814
  • Padovani, Alessandro|||0000-0002-0119-3639
  • Almeida, Maria Rosário|||0000-0001-9289-3835
  • Santana, Isabel|||0000-0002-8114-9434
  • Diehl-Schmid, Janine|||0000-0002-7745-1382
  • Alexopoulos, Panagiotis|||0000-0002-9047-6365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Koutroumani, Maria
  • Matej, Radoslav|||0000-0002-6152-6343
  • Rohan, Zdenek|||0000-0003-3501-6179
  • De Deyn, Peter Paul|||0000-0002-2228-2964
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Cras, Patrick|||0000-0002-7265-7429
  • Van Broeckhoven, Christine|||0000-0003-0183-7665
  • Sleegers, Kristel|||0000-0002-0283-2332
Premature termination codon (PTC) mutations in the ATP-Binding Cassette, Sub-Family A, Member 7 gene (ABCA7) have recently been identified as intermediate-to-high penetrant risk factor for late-onset Alzheimer's disease (LOAD). High variability, however, is observed in downstream ABCA7 mRNA and protein expression, disease penetrance, and onset age, indicative of unknown modifying factors. Here, we investigated the prevalence and disease penetrance of ABCA7 PTC mutations in a large early onset AD (EOAD)-control cohort, and examined the effect on transcript level with comprehensive third-generation long-read sequencing. We characterized the ABCA7 coding sequence with next-generation sequencing in 928 EOAD patients and 980 matched control individuals. With MetaSKAT rare variant association analysis, we observed a fivefold enrichment (p = 0.0004) of PTC mutations in EOAD patients (3%) versus controls (0.6%). Ten novel PTC mutations were only observed in patients, and PTC mutation carriers in general had an increased familial AD load. In addition, we observed nominal risk reducing trends for three common coding variants. Seven PTC mutations were further analyzed using targeted long-read cDNA sequencing on an Oxford Nanopore MinION platform. PTC-containing transcripts for each investigated PTC mutation were observed at varying proportion (5-41% of the total read count), implying incomplete nonsense-mediated mRNA decay (NMD). Furthermore, we distinguished and phased several previously unknown alternative splicing events (up to 30% of transcripts). In conjunction with PTC mutations, several of these novel ABCA7 isoforms have the potential to rescue deleterious PTC effects. In conclusion, ABCA7 PTC mutations play a substantial role in EOAD, warranting genetic screening of ABCA7 in genetically unexplained patients. Long-read cDNA sequencing revealed both varying degrees of NMD and transcript-modifying events, which may influence ABCA7 dosage, disease severity, and may create opportunities for therapeutic interventions in AD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The behavioral and psychological symptoms of dementia in Down syndrome (BPSD-DS) scale, comprehensive assessment of psychopathology in Down syndrome

  • Dekker, Alain D.|||0000-0001-8771-218X
  • Sacco, Silvia
  • Carfi, Angelo|||0000-0002-9837-7003
  • Benejam, Bessy|||0000-0002-6789-8615
  • Vermeiren, Yannick|||0000-0002-2091-5326
  • Beugelsdijk, Gonny
  • Schippers, Mieke
  • Hassefras, Lyanne
  • Eleveld, José
  • Grefelman, Sharina
  • Fopma, Roelie
  • Bomer-Veenboer, Monique
  • Botí, M.|||0000-0003-2963-6929
  • Oosterling, G. Danielle E.
  • Scholten, Esther
  • Tollenaere, Marleen
  • Checkley, Laura
  • Strydom, André
  • Van Goethem, Gert
  • Onder, Graziano
  • Blesa, Rafael|||0000-0003-4026-2884
  • zu Eulenburg, Christine
  • Coppus, Antonia
  • Rebillat, Anne-Sophie|||0000-0003-1995-9177
  • Fortea, Juan|||0000-0002-1340-638X
  • De Deyn, Peter Paul|||0000-0002-2228-2964
People with Down syndrome (DS) are prone to develop Alzheimer's disease (AD). Behavioral and psychological symptoms of dementia (BPSD) are core features, but have not been comprehensively evaluated in DS. In a European multidisciplinary study, the novel Behavioral and Psychological Symptoms of Dementia in Down Syndrome (BPSD-DS) scale was developed to identify frequency and severity of behavioral changes taking account of life-long characteristic behavior. 83 behavioral items in 12 clinically defined sections were evaluated. The central aim was to identify items that change in relation to the dementia status, and thus may differentiate between diagnostic groups. Structured interviews were conducted with informants of persons with DS without dementia (DS, n = 149), with questionable dementia (DS+Q, n = 65), and with diagnosed dementia (DS+AD, n = 67). First exploratory data suggest promising interrater, test-retest, and internal consistency reliability measures. Concerning item relevance, group comparisons revealed pronounced increases in frequency and severity in items of anxiety, sleep disturbances, agitation & stereotypical behavior, aggression, apathy, depressive symptoms, and eating/drinking behavior. The proportion of individuals presenting an increase was highest in DS+AD, intermediate in DS+Q, and lowest in DS. Interestingly, among DS+Q individuals, a substantial proportion already presented increased anxiety, sleep disturbances, apathy, and depressive symptoms, suggesting that these changes occur early in the course of AD. Future efforts should optimize the scale based on current results and clinical experiences, and further study applicability, reliability, and validity. Future application of the scale in daily care may aid caregivers to understand changes, and contribute to timely interventions and adaptation of caregiving.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Perspectives on ethnic and racial disparities in Alzheimer's disease and related dementias, Update and areas of immediate need

  • Babulal, Ganesh Muneshwar
  • Quiroz, Yakeel T.|||0000-0001-9714-8244
  • Albensi, Benedict Charles
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Astell, Arlene|||0000-0002-6822-9472
  • Babiloni, Claudio|||0000-0002-5245-9839
  • Bahar-Fuchs, Alex|||0000-0002-9248-6057
  • Bell, Joanne M.
  • Bowman, Gene|||0000-0003-0111-1565
  • Brickman, Adam|||0000-0002-5125-8226
  • Chételat, G.|||0000-0002-4889-7932
  • Ciro, Carrie A.
  • Cohen, Ann D.
  • Dilworth-Anderson, Peggye
  • Dodge, Hiroko Hayama
  • Dreux, Simone
  • Edland, Steven D.
  • Esbensen, Anna J.
  • Evered, Lisbeth A.
  • Ewers, Michael|||0000-0001-5231-1714
  • Fargo, Keith N.|||0000-0002-6515-2342
  • Fortea, Juan|||0000-0002-1340-638X
  • González, Héctor M.
  • Gustafson, Deborah Ruth
  • Head, Elizabeth H.
  • Hendrix, James A.
  • Hofer, Scott M.|||0000-0001-8923-4337
  • Johnson, Leigh A.
  • Jutten, Roos J.|||0000-0002-3712-4790
  • Kilborn, Kerry W.
  • Lanctôt, Krista L.
  • Manly, Jennifer Jaie
  • Martins, Ralph|||0000-0002-4828-9363
  • Mielke, Michelle M.
  • Morris, Martha Clare
  • Murray, Melissa E.
  • Oh, E. S.
  • Parra, Mario A.
  • Rissman, Robert A.|||0000-0001-9245-8278
  • Roe, C. M.
  • Santos, Octavio A.
  • Scarmeas, N.
  • Schneider, L. S.
  • Schupf, N.
  • Sikkes, S.
  • Snyder, H. M.
  • Sohrabi, H. R.
  • Stern, Y.
  • Strydom, A.
  • Tang, Yi|||0000-0002-2594-6068
  • Terrera, Graciela Muniz
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • Melo van Lent, D.
  • Weinborn, M.
  • Wesselman, L.
  • Wilcock, D. M.
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • O'Bryant, S. E.
Alzheimer's disease and related dementias (ADRDs) are a global crisis facing the aging population and society as a whole. With the numbers of people with ADRDs predicted to rise dramatically across the world, the scientific community can no longer neglect the need for research focusing on ADRDs among underrepresented ethnoracial diverse groups. The Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART; alz.org/ISTAART) comprises a number of professional interest areas (PIAs), each focusing on a major scientific area associated with ADRDs. We leverage the expertise of the existing international cadre of ISTAART scientists and experts to synthesize a cross-PIA white paper that provides both a concise "state-of-the-science" report of ethnoracial factors across PIA foci and updated recommendations to address immediate needs to advance ADRD science across ethnoracial populations.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Challenges associated with biomarker-based classification systems for Alzheimer's disease

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dickerson, Bradford C.
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • de Leon, Mony J..
  • Blesa, Rafael|||0000-0003-4026-2884
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
We aimed to evaluate the consistency of the A/T/N classification system. We included healthy controls, mild cognitive impairment, and dementia patients from Alzheimer's disease Neuroimaging Initiative. We assessed subject classification consistency with different biomarker combinations and the agreement and correlation between biomarkers. Subject classification discordance ranged from 12.2% to 44.5% in the whole sample; 17.3%-46.4% in healthy controls; 11.9%-46.5% in mild cognitive impairment, and 1%-35.7% in dementia patients. Amyloid, but not neurodegeneration biomarkers, showed good agreement both in the whole sample and in the clinical subgroups. Amyloid biomarkers were correlated in the whole sample, but not along the Alzheimer's disease continuum (as defined by a positive amyloid positron emission tomography). Neurodegeneration biomarkers were poorly correlated both in the whole sample and along the Alzheimer's disease continuum. The relationship between biomarkers was stage-dependent. Our findings suggest that the current A/T/N classification system does not achieve the required consistency to be used in the clinical setting.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Dense core vesicle markers in CSF and cortical tissues of patients with Alzheimer's disease

  • Barranco, Neus|||0000-0002-6488-0815
  • Plá, Virginia|||0000-0002-5501-0789
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Sánchez-Domínguez, Irene|||0000-0001-6421-8293
  • Fischer-Colbrie, Reiner
  • Ferrer, Isidro|||0000-0001-9888-8754
  • Lleó, Alberto|||0000-0002-2568-5478
  • Aguado, Fernando|||0000-0002-0393-1308
New fluid biomarkers for Alzheimer's disease (AD) that reveal synaptic and neural network dysfunctions are needed for clinical practice and therapeutic trial design. Dense core vesicle (DCV) cargos are promising cerebrospinal fluid (CSF) indicators of synaptic failure in AD patients. However, their value as biomarkers has not yet been determined. Immunoassays were performed to analyze the secretory proteins prohormone convertases PC1/3 and PC2, carboxypeptidase E (CPE), secretogranins SgIII and SgII, and Cystatin C in the cerebral cortex (n = 45, provided by Bellvitge University Hospital) and CSF samples (n = 66, provided by The Sant Pau Initiative on Neurodegeneration cohort) from AD patients (n = 56) and age-matched controls (n = 55). In AD tissues, most DCV proteins were aberrantly accumulated in dystrophic neurites and activated astrocytes, whereas PC1/3, PC2 and CPE were also specifically accumulated in hippocampal granulovacuolar degeneration bodies. AD individuals displayed an overall decline of secretory proteins in the CSF. Interestingly, in AD patients, the CSF levels of prohormone convertases strongly correlated inversely with those of neurodegeneration markers and directly with cognitive impairment status. These results demonstrate marked alterations of neuronal-specific prohormone convertases in CSF and cortical tissues of AD patients. The neuronal DCV cargos are biomarker candidates for synaptic dysfunction and neurodegeneration in AD. The online version contains supplementary material available at 10.1186/s40035-021-00263-0.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex differences in the behavioral variant of frontotemporal dementia, A new window to executive and behavioral reserve

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Casaletto, Kaitlin B.
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Arenaza-Urquijo, Eider|||0000-0001-7016-7576
  • Wolf, Amy
  • Cobigo, Yann|||0000-0002-0354-4092
  • Goh, Sheng Yang M.
  • Staffaroni, Adam M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Iulita, M. Florencia|||0000-0002-3360-4498
  • Brugulat-Serrat, Anna
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Grinberg, Lea T.
  • Possin, Katherine
  • Rankin, Katherine P.
  • Kramer, Joel H.|||0000-0002-2917-8297
  • Rabinovici, Gil D.
  • Boxer, Adam
  • Seeley, William W.
  • Sturm, Virginia E.
  • Gorno-Tempini, Maria Luisa
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Perry, David C.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rosen, Howard J.|||0000-0001-9281-7402
Biological sex is an increasingly recognized factor driving clinical and structural heterogeneity in Alzheimer's disease, but its role in the behavioral variant of frontotemporal dementia (bvFTD) is unknown. We included 216 patients with bvFTD and 235 controls with magnetic resonance imaging (MRI) from a large multicenter cohort. We compared the clinical characteristics and cortical thickness between men and women with bvFTD and controls. We followed the residuals approach to study behavioral and cognitive reserve. At diagnosis, women with bvFTD showed greater atrophy burden in the frontotemporal regions compared to men despite similar clinical characteristics. For a similar amount of atrophy, women demonstrated better-than-expected scores on executive function and fewer changes in apathy, sleep, and appetite than men. Our findings suggest that women might have greater behavioral and executive reserve than men, and neurodegeneration must be more severe in women to produce symptoms similar in severity to those in men.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of Magnetic Resonance Imaging Measures of Brain Atrophy Across the Spectrum of Progressive Supranuclear Palsy and Corticobasal Degeneration

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Nigro, Salvatore
  • Vandevrede, Lawren
  • Falgàs, Neus|||0000-0002-3404-2765
  • Heuer, Hilary W.
  • Painous, Cèlia|||0000-0002-7027-3093
  • Compta, Yaroslau|||0000-0001-6443-0104
  • Martí Domenech, Maria Josep|||0000-0002-9872-7835
  • Montal, Victor|||0000-0002-5714-9282
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Kulisevsky, Jaime|||0000-0003-4870-1431
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Logroscino, Giancarlo|||0000-0003-0423-3242
  • Quattrone, Andrea
  • Perry, David C.
  • Gorno-Tempini, Maria Luisa
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Grinberg, Lea T.
  • Spina, Salvatore
  • La Joie, Renaud
  • Rabinovici, Gil D.
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Rojas, Julio C.|||0000-0002-1308-646X
  • Seeley, William W.
  • Boxer, Adam
Importance: The accurate diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) is hampered by imperfect clinical-pathological correlations. Objective: To assess and compare the diagnostic value of the magnetic resonance parkinsonism index (MRPI) and other magnetic resonance imaging-based measures of cerebral atrophy to differentiate between PSP, CBD, and other neurodegenerative diseases. Design, Setting, and Participants: This prospective diagnostic study included participants with 4-repeat tauopathies (4RT), PSP, CBD, other neurodegenerative diseases and available MRI who appeared in the University of California, San Francisco, Memory and Aging Center database. Data were collected from October 27, 1994, to September 29, 2019. Data were analyzed from March 1 to September 14, 2021. Main Outcomes and Measures: The main outcome of this study was the neuropathological diagnosis of PSP or CBD. The clinical diagnosis at the time of the MRI acquisition was noted. The imaging measures included the MRPI, cortical thickness, subcortical volumes, including the midbrain, pons, and superior cerebellar peduncle volumes. Multinomial logistic regression models (MLRM) combining different cortical and subcortical regions were defined to discriminate between PSP, CBD, and other pathologies. The areas under the receiver operating characteristic curves (AUROC) and cutoffs were calculated to differentiate between PSP, CBD, and other diseases. Results: Of the 326 included participants, 176 (54%) were male, and the mean (SD) age at MRI was 64.1 (8.0) years. The MRPI showed good diagnostic accuracy for the differentiation between PSP and all other pathologies (accuracy, 87%; AUROC, 0.90; 95% CI, 0.86-0.95) and between 4RT and other pathologies (accuracy, 80%; AUROC, 0.82; 95% CI, 0.76-0.87), but did not allow the discrimination of participants with CBD. Its diagnostic accuracy was lower in the subgroup of patients without the canonical PSP-Richardson syndrome (PSP-RS) or probable corticobasal syndrome (CBS) at MRI. MLRM combining cortical and subcortical measurements showed the highest accuracy for the differentiation between PSP and other pathologies (accuracy, 95%; AUROC, 0.98; 95% CI, 0.97-0.99), CBD and other pathologies (accuracy, 83%; AUROC, 0.86; 95% CI, 0.81-0.91), 4RT and other pathologies (accuracy, 89%; AUROC, 0.94; 95% CI, 0.92-0.97), and PSP and CBD (accuracy, 91%; AUROC, 0.95; 95% CI, 0.91-0.99), even in participants without PSP-RS or CBS at MRI. Conclusions and Relevance: In this study, the combination of widely available cortical and subcortical measures of atrophy on MRI discriminated between PSP, CBD, and other pathologies and could be used to support the diagnosis of 4RT in clinical practice.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Cortical microstructure in primary progressive aphasia, a multicenter study

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Mandelli, Maria Luisa|||0000-0002-2518-2520
  • Falgàs, Neus|||0000-0002-3404-2765
  • Welch, Ariane E.
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Blesa, Rafael|||0000-0003-4026-2884
  • Dickerson, Bradford C.
  • Rosen, Howard J.|||0000-0001-9281-7402
  • Miller, Bruce L.|||0000-0002-2152-4220
  • Lleó, Alberto|||0000-0002-2568-5478
  • Gorno-Tempini, Maria Luisa
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
Background: Cortical mean diffusivity is a novel imaging metric sensitive to early changes in neurodegenerative syndromes. Higher cortical mean diffusivity values reflect microstructural disorganization and have been proposed as a sensitive biomarker that might antedate macroscopic cortical changes. We aimed to test the hypothesis that cortical mean diffusivity is more sensitive than cortical thickness to detect cortical changes in primary progressive aphasia (PPA). Methods: In this multicenter, case-control study, we recruited 120 patients with PPA (52 non-fluent, 31 semantic, and 32 logopenic variants; and 5 GRN-related PPA) as well as 89 controls from three centers. The 3-Tesla MRI protocol included structural and diffusion-weighted sequences. Disease severity was assessed with the Clinical Dementia Rating scale. Cortical thickness and cortical mean diffusivity were computed using a surface-based approach. Results: The comparison between each PPA variant and controls revealed cortical mean diffusivity increases and cortical thinning in overlapping regions, reflecting the canonical loci of neurodegeneration of each variant. Importantly, cortical mean diffusivity increases also expanded to other PPA-related areas and correlated with disease severity in all PPA groups. Cortical mean diffusivity was also increased in patients with very mild PPA when only minimal cortical thinning was observed and showed a good correlation with measures of disease severity. Conclusions: Cortical mean diffusivity shows promise as a sensitive biomarker for the study of the neurodegeneration-related microstructural changes in PPA.